News - Page 70 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Post published:January 20, 2023
Post category:Press Release

Read more about the article FILAMENT HEALTH ANNOUNCES CLINICAL TRIAL APPROVAL IN PARTNERSHIP WITH PSYCHIATRIC CENTRE COPENHAGEN

FILAMENT HEALTH ANNOUNCES CLINICAL TRIAL APPROVAL IN PARTNERSHIP WITH PSYCHIATRIC CENTRE COPENHAGEN

Post published:January 20, 2023
Post category:Press Release

Read more about the article Numinus Wellness Inc. Reports Q1 2023 Results

Numinus Wellness Inc. Reports Q1 2023 Results

Post published:January 19, 2023
Post category:Press Release

Read more about the article “After the Ecstasy, the Laundry” – Shayla Love’s Take on Psychedelics in 2022

“After the Ecstasy, the Laundry” – Shayla Love’s Take on Psychedelics in 2022

Post published:January 19, 2023
Post category:2022 Year in Review

Read more about the article Psychedelics 2022: A Year in Review

Psychedelics 2022: A Year in Review

Post published:January 19, 2023
Post category:2022 Year in Review

Read more about the article PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

Post published:January 18, 2023
Post category:Press Release

Read more about the article Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements

Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements

Post published:January 18, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Post published:January 17, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Post published:January 17, 2023
Post category:Press Release

Read more about the article First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026

First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026

Post published:January 15, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.